一项基于人群的7114例弥漫大B细胞淋巴瘤患者队列的长期生存与预期寿命损失
该研究基于瑞典淋巴瘤登记库纳入2000-2013年诊断的7114例弥漫大B细胞淋巴瘤(DLBCL)患者,按年龄校正的国际预后指数(aaIPI)分层,采用灵活参数模型预测预期寿命损失(LEL)。研究期间DLBCL导致的平均LEL从8.0年降至4.6年,但aaIPI≥2分且50-60岁患者2013年仍估计损失超过8年。2年生存者的LEL在aaIPI≥2组和<2组分别降至1.1年和1.0年。
要点
- 研究期间DLBCL导致的平均LEL从8.0年降至4.6年。
- aaIPI≥2分且50-60岁患者2013年仍估计损失超过8年。
- 2年生存者LEL在aaIPI≥2组降至1.1年、<2组降至1.0年。
核心结论
- 通过LEL指标显示DLBCL生存随时间改善,但尽管接受充分免疫化疗,IPI≥2分患者仍有 substantial LEL,提示存在未满足的医疗需求。
- 作者推测2年生存者中观察到的LEL降低可能提示晚期复发减少。
研究设计与样本
- 基于瑞典淋巴瘤登记库的全国性人群队列研究,纳入2000-2013年诊断的DLBCL患者7114例,按aaIPI分类。
- LEL定义为患者剩余寿命与一般人群剩余寿命之差,采用灵活参数模型从诊断时及2年生存者中按年龄和性别预测。
主要发现
- 诊断时中位年龄为70岁(范围18-105岁),54.8%的患者为III-IV期。
- 研究期间DLBCL导致的平均LEL从8.0年(95%CI:7.7-8.3)降至4.6年(95%CI:4.5-4.6)。
- 按风险组,aaIPI≥2分且50-60岁患者LEL降低最明显,但2013年这些患者仍估计损失超过8年(例如50岁男性LEL为8.6年(95%CI:5.0-12.3))。
- 2年生存者中,aaIPI≥2组LEL从6.1年(95%CI:5.6-6.5)降至1.1年(95%CI:1.1-1.2),aaIPI<2组从3.8年(95%CI:3.6-4.1)降至1.0年(95%CI:0.8-1.1),各年龄段均观察到降低,女性结果相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of anti-CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population-based level. Patients diagnosed with DLBCL 2000-2013 (N = 7114) were identified through the Swedish Lymphoma Registry and classified according to the age-adjusted International Prognostic Index (aaIPI). The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2-year survivors, by age and sex. Median age at DLBCL-diagnosis was 70 (18-105) years and 54.8% presented with stage III-IV disease. On average, LEL due to DLBCL decreased from 8.0 (95% CI: 7.7-8.3) to 4.6 (95% CI: 4.5-4.6) years over the study period. By risk group, LEL was most reduced among patients with aaIPI ≥2 aged 50-60 years. However, these patients were still estimated to lose >8 years in 2013 (eg, LELmales50years 8.6 years (95% CI: 5.0-12.3)). Among 2-year survivors, LEL was reduced from 6.1 years (95% CI: 5.6-6.5) (aaIPI ≥ 2) and 3.8 years (95% CI: 3.6-4.1) (aaIPI < 2) to 1.1 (95% CI: 1.1-1.2) and 1.0 year (95% CI: 0.8-1.1), respectively. The reduction was observed across all ages. Results for females were similar. By using LEL we illustrate the improvement of DLBCL survival over time. Despite adequate immunochemotherapy, substantial LEL among patients with IPI ≥ 2 points to remaining unmet medical needs. We speculate that observed reduced losses among 2-year survivors indicate a reduction of late relapses.
引用
- Ekberg S, Jerkeman M, Andersson PO, et al. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. Am J Hematol. 2018. PMID: 29770496. doi:10.1002/ajh.25147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。